TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05557474

Intervention type: OTHER
Intervention: Early-stage lung cancer prognostic kit -- ELISA
Description: blood sample with ELISA

Intervention type: OTHER
Intervention: Early-stage lung cancer prognostic kit -- IHC
Description: surgical tumor part with IHC
Study: NCT05616234

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Participants will perform a bout of lower body resistance exercise consisting of leg press, leg extension and leg curls.
Study: NCT04634162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor
Description: Cangrelor will be used at the FDA recommended dose using a 30 μg/kg bolus followed by 4 μg/kg/min infusion. The duration of cangrelor/placebo infusion will be 2 hours. After completing the first phase of the study, patients will undergo a 1-4 week wash-out period and then will cross-over to the alternative treatment in the second phase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cangrelor
Description: Cangrelor will be used at the FDA recommended dose using a 30 μg/kg bolus followed by 4 μg/kg/min infusion. The duration of cangrelor/placebo infusion will be 2 hours. After completing the first phase of the study, patients will undergo a 1-4 week wash-out period and then will cross-over to the alternative treatment in the second phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline will be infused for 2 hours. After completing the first phase of the study, patients will undergo a 1-4 week wash-out period and then will cross-over to the alternative treatment in the second phase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline will be infused for 2 hours. After completing the first phase of the study, patients will undergo a 1-4 week wash-out period and then will cross-over to the alternative treatment in the second phase
Study: NCT05067660

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy
Description: Stereotactic ablative radiotherapy (SABR) is a highly focused radiation treatment that concentrates an intense dose of radiation on the recurrent tumorous lesion while limiting the dose to healthy surrounding tissues.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Current standard template-based salvage therapy
Description: In the group receiving salvage radiotherapy according to current standard of care, radiation will be directed to the prostatic bed and pelvic lymph nodes according to the radiation oncologist's discretion.
Study: NCT05331365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Construction and evaluation of a composite score evaluating post ankle surgery residual instability by completing questionnaires and undergoing physical tests
Description: Four tests and two questionnaires, each evaluating specific physical or psychological dimensions will be used to construct the composite score Ankle Go Test composite score:~* Foot and Ankle Ability Measure Questionnaire (FAAM)~* Ankle ligament reconstruction-return to sport after injury Questionnaire(ALR-RSI)~* Single Leg Stance Test (SLST)~* Side Hop Test (SHT)~* Star Excursion Balance Test (SEBT)~* Figure-of-8

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Construction and evaluation of a composite score evaluating post ankle surgery residual instability by completing questionnaires and undergoing physical tests
Description: Four tests and two questionnaires, each evaluating specific physical or psychological dimensions will be used to construct the composite score Ankle Go Test composite score:~* Foot and Ankle Ability Measure Questionnaire (FAAM)~* Ankle ligament reconstruction-return to sport after injury Questionnaire(ALR-RSI)~* Single Leg Stance Test (SLST)~* Side Hop Test (SHT)~* Star Excursion Balance Test (SEBT)~* Figure-of-8
Study: NCT06590558

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT04859114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Displayed chance of survival
Description: In the outcome data provided to participants, they view either a 30% or 60% chance of survival.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Displayed chance of survival
Description: In the outcome data provided to participants, they view either a 30% or 60% chance of survival.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Displayed chance of survival
Description: In the outcome data provided to participants, they view either a 30% or 60% chance of survival.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Displayed chance of survival
Description: In the outcome data provided to participants, they view either a 30% or 60% chance of survival.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Displayed chance of survival
Description: In the outcome data provided to participants, they view either a 30% or 60% chance of survival.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Displayed chance of survival
Description: In the outcome data provided to participants, they view either a 30% or 60% chance of survival.
Study: NCT06626620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulphate infusion
Description: Received IV magnesium sulfate (50 mg/kg up to a maximum dose of 2 g) administered over 20 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbutaline Infusion
Description: Received IV terbutaline (10 mcg/kg bolus followed by a continuous infusion of 0.4 mcg/kg/min) for up to 4 hours
Study: NCT06627660

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Valsalva maneuver
Description: Closure of the nose and mouth during expiration for 20 sec
Study: NCT06627543

Intervention type: DIAGNOSTIC_TEST
Intervention: echo
Description: echocardiographic
Study: NCT06725186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RELAX
Description: The RELAX intervention is a social-emotional intervention consisting of 8 weekly, 1.5 hr sessions and a booster session 1 month and 6 months after the completion of RELAX. During the first 60 minutes of RELAX sessions, parents and adolescents meet separately; during the last 30 minutes combined parent-adolescent discussion and problem-solving activities take place. RELAX is structured such that parents learn emotion regulation/coping skills the week prior to them being taught to the adolescents. Group sessions will involve both didactics and discussion of topics including psychoeducation, basic cognitive/behavioral principles, emotional awareness, emotion regulation strategies, parent emotion socialization practices, coping skills, conflict management strategies, and communication skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational Materials
Description: Infographics with information on emotion regulation development, emotion regulation strategies, and strategies for managing interpersonal conflict, including when different strategies are more or less effective will be provided to participants via email.
Study: NCT06737354

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: IVB103 Injection（Low dose）
Description: Single intravitreal injection

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: IVB103 Injection（Intermediate dose）
Description: Single intravitreal injection

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: IVB103 Injection（High dose）
Description: Single intravitreal injection
Study: NCT06738277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bmab 1200 (Biosimilar Ustekinumab)
Description: Dosage Form: injection, Strength(s): 45 mg/ 0.5 mL Route of Administration: Subcutaneous Frequency and Dose: 45 mg, single dose
Study: NCT06590558

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT04666961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg
Description: Tamoxifen will be initiated in non menopausal patients orally for 6 months in a neoadjuvant situation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole 1Mg Tab
Description: Anastrozole will be initiated in menopausal patients orally for 6 months in a neoadjuvant situation.
Study: NCT05362162

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cervical plexus block
Description: local anesthetic agent injection into the either Superficial or intermediate area

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cervical plexus block
Description: local anesthetic agent injection into the either Superficial or intermediate area
Study: NCT05190575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TST001
Description: TST001 IV infusion every 3 weeks until disease progression or other discontinuation criteria.
Study: NCT06590558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT06738277

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bmab 1200 (Biosimilar Ustekinumab)
Description: Dosage Form: injection, Strength(s): 45 mg/ 0.5 mL Route of Administration: Subcutaneous Frequency and Dose: 45 mg, single dose
Study: NCT06741423

Intervention type: OTHER
Intervention: Radiomics Algortihm
Description: A radiomics algorithm designed to distinguish retroperitoneal fibrosis from other retroperitoneal tumors and provide recommendations for clinical treatment decisions.

Intervention type: OTHER
Intervention: Radiomics Algortihm
Description: A radiomics algorithm designed to distinguish retroperitoneal fibrosis from other retroperitoneal tumors and provide recommendations for clinical treatment decisions.

Intervention type: OTHER
Intervention: Radiomics Algortihm
Description: A radiomics algorithm designed to distinguish retroperitoneal fibrosis from other retroperitoneal tumors and provide recommendations for clinical treatment decisions.
Study: NCT06742866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone Injection
Description: Administer 300 mg of intravenous amiodarone as a loading dose once daily (QD) and 200 mg of oral amiodarone twice daily (BID) within 24 hours postoperatively, and continue for 3 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride Injection 0.9%
Description: Sodium chloride injection as a placebo in an amount equivalent to amiodarone injection.
Study: NCT06743425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RAMP Reports
Description: Participants will receive text-based requests for reports with embedded links to select radio button questionnaires directly on their mobile device. Questions include current inattention/hyperactivity symptoms, school performance, and any engagement in behavioral therapy. Inattention/hyperactivity symptom questions and scoring is taken directly from the publicly available Vanderbilt Rating Scales, which is a commonly used, guideline-recommended tool for both diagnosis and management of ADHD for use by parents and teachers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital Education Handouts
Description: The digital education handouts will be sent via email to the control group and will serve as an attention control. They will consist of information regarding a general pediatric health topic and will be emailed at intervals matching the RAMP requests in the intervention group.
Study: NCT06590558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolinapant
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo chest X-ray
Study: NCT06741826

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Navigation bronchoscopy combined with radial endobronchial ultrasound guided pulmonary nodule biopsy under needle-based confocal laser endomicroscopy.
Description: Navigation bronchoscopy combined with radial endobronchial ultrasound guided pulmonary nodule biopsy under needle-based confocal laser endomicroscopy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Navigation bronchoscopy combined with radial endobronchial ultrasound guided pulmonary nodule biopsy under needle-based confocal laser endomicroscopy.
Description: Navigation bronchoscopy combined with radial endobronchial ultrasound guided pulmonary nodule biopsy under needle-based confocal laser endomicroscopy.
Study: NCT06741618

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MyPEEPS Mobile
Description: An evidence-based, digitally delivered mHealth sexual risk reduction intervention on HIV incidence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyPEEPS Mobile
Description: An evidence-based, digitally delivered mHealth sexual risk reduction intervention on HIV incidence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic PrEP peer navigation
Description: Electronic peer navigation to PreP services
Study: NCT06743230

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuro athletic training
Description: The neuroathletic training includes exercises that stimulate the visual, vestibular, and proprioceptive systems. The neuroathletic training includes 3 days per week for 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional training
Description: Conventional training includes flexibility exercises, strengthening exercises, running, balance and sport-specific technique work 5 days per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional training
Description: Conventional training includes flexibility exercises, strengthening exercises, running, balance and sport-specific technique work 5 days per week.
Study: NCT06742177

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group Bi-level ESPB
Description: The block procedure is performed immediately before surgery begins after general anesthesia induction, with the patient in the lateral decubitus position. For the block, sterile conditions are provided with USG, and the erector spinae muscle and vertebral process are visualized, and the in plane technique is used. The target vertebral level for bi-level ESPB is two levels, T5 and T7. The block needle is advanced in the caudo-cranial direction, and the potential area between the erector spinae muscle and the transverse process of the relevant vertebra is targeted. The block location is confirmed by injecting 2 ml of saline between the transverse process and the muscle. After the block location is confirmed, a total of 40 ml of 0.25% bupivacaine is applied, using 20 ml of 0.25% bupivacaine for a single level.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group M-TAPA block
Description: The procedure is performed in the supine position immediately before surgery after general anesthesia induction and the in plane technique is used. The transversus abdominis, internal oblique and external oblique muscles are identified at the costochondral angle in the sagittal plane under ultrasound guidance at the 10th costal margin. The block needle is advanced in the caudo-cranial direction and a deep angle is given with the probe in the sagittal direction to the costochondral angle at the edge of the 10th rib to visualize the lower surface of the costal cartilage in the midline. The block location is confirmed by injecting 2 ml of saline onto the transverse abdominis muscle under the 10th costal cartilage. After the block location is confirmed, 20 ml of 0.25% bupivacaine is used. This procedure is repeated for the opposite side and a total of 40 ml of 0.25% bupivacaine is used.
Study: NCT06742502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintlimab+Rituximab follwed by R-CHOP(Cyclophosphamide, doxorubicin, vincristine, prednisone)
Description: First strategy of targeted immunotherapy followed by chemotherapy for PMBL. Participants will first receive sintilimab(200mg) plus rituximab(375mg/m2) for 2 cycles. If patients achieve CR or CMR, they will continue to receive 2 courses of sintilimab plus rituximab, followed by 4 cycles of R-CHOP. Patients will receive 6 courses of R-CHOP if they do not achieve CR or CMR after 2 cycles of sintilimab plus rituximab. Patients will undergo PET-CT assessment and will receive 6 cycles of maintenance treatment with nintedanib if CR/CMR/PR is achieved and will be withdrawn from the study if SD/PD occurs. Total treatment cycles will not exceed 14 cycles.
Study: NCT06742840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-2129
Description: HRS-2129.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HRS-2129 placebo
Description: HRS-2129 placebo.
Study: NCT04888338

Intervention type: OTHER
Intervention: Data Capture
Description: Treatment related data is collected

Intervention type: OTHER
Intervention: Electronic Medical Record
Description: Medical records are reviewed
Study: NCT05068284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-154
Description: Intravenous (IV) Infusion; Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-154
Description: Intravenous (IV) Infusion; Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-154
Description: Intravenous (IV) Infusion; Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-154
Description: Intravenous (IV) Infusion; Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-154
Description: Intravenous (IV) Infusion; Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-154
Description: Intravenous (IV) Infusion; Subcutaneous Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous (IV) infusion; Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-154
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-154
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous Injection
Study: NCT05796336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lip taping
Description: Steri strip tape and passive baby feeding plate Two methods of lip taping will be used with passive baby feeding plate. Impressions will be taken before starting the treatment (T1) and at the end of treatment (T2) three months later. The effectiveness of the two appliances will be assessed and measured on digital models of the maxillary arch before and after the treatment.
Study: NCT05068284

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous Injection
Study: NCT06548958

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Second Stem Cell Transplantation (SCT2)
Description: 1. Conditioning Regimen Day -7: Semustine (Me-CCNU) 250mg/m², orally; Day -6: Total Body Irradiation (TBI) 4Gy; Day -5 to Day -4: Busulfan (Bu) 3.2mg/kg/day, administered in four divided doses, IV infusion; Day -3 to Day -2: Melphalan (Mel) 50mg/m²/day, IV infusion;~2. Donor Stem Cell Infusion (Second Hematopoietic Stem Cell Transplantation) Day 0: Intravenous infusion of donor hematopoietic stem cells (MNC ≥ 8×10⁸/kg, CD34+ cells ≥ 4×10⁶/kg).
Study: NCT05792254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier granule
Description: Oral Huai Er granules, 20 g once, 3 times a day, continued to progress or intolerance toxicity.
Study: NCT05038904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: 100 mg oral capsule
Study: NCT04773600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast Cream
Description: Roflumilast cream 0.15% for topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: Vehicle cream for topical application
Study: NCT05315297

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEMF device
Description: PEMF device wear overnight daily for four weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham PEMF device
Description: Sham PEMF device wear overnight daily for four weeks. Sham PEMF devices do not emit a radiofrequency electromagnetic field but are otherwise identical in appearance to the PEMF device
Study: NCT06084416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sovilnesib
Description: Sovilnesib tablets will be given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sovilnesib
Description: Sovilnesib tablets will be given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sovilnesib
Description: Sovilnesib tablets will be given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sovilnesib
Description: Sovilnesib tablets will be given orally.
Study: NCT04319822

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample and muscular biopsy
Description: blood sample and muscular biopsy
Study: NCT06531122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban 5MG
Description: 100 CVT patients will receive apixaban 5mg Bid for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 20 MG Oral Tablet
Description: 100 CVT patients will receive Rivaroxaban 20mg daily for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire